[go: up one dir, main page]

WO2007009758A2 - Composes chimiques - Google Patents

Composes chimiques Download PDF

Info

Publication number
WO2007009758A2
WO2007009758A2 PCT/EP2006/007080 EP2006007080W WO2007009758A2 WO 2007009758 A2 WO2007009758 A2 WO 2007009758A2 EP 2006007080 W EP2006007080 W EP 2006007080W WO 2007009758 A2 WO2007009758 A2 WO 2007009758A2
Authority
WO
WIPO (PCT)
Prior art keywords
compound
formula
treatment
compounds
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2006/007080
Other languages
English (en)
Other versions
WO2007009758A3 (fr
Inventor
Silvia Martinucci
Andrew Roberts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of WO2007009758A2 publication Critical patent/WO2007009758A2/fr
Publication of WO2007009758A3 publication Critical patent/WO2007009758A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Definitions

  • the present invention relates to a 4-acetyl-3-hydroxy-1-piperazinyl derivative, salts and solvates thereof, to processes for their preparation, to pharmaceutical compositions containing them and to their medical use
  • WO 03/06621 and WO 02/32867 disclose certain 2-aryl 1 ,4-disubstituted piperidine derivatives as NK1 antagonists.
  • the present invention provides, in one aspect, a compound of formula (I) ,
  • Suitable pharmaceutically acceptable salts of the compounds of general formula (I) include acid addition salts formed with pharmaceutically acceptable organic or inorganic acids, for example hydrochlorides, hydrobromides, sulphates, alkyl- or arylsulphonates (e.g. methansulphonates or p-toluenesulphonates), phosphates, trifluoroacetates, acetates, citrates, succinates, tartrates, lactates, malates, fumarates and maleates.
  • pharmaceutically acceptable organic or inorganic acids for example hydrochlorides, hydrobromides, sulphates, alkyl- or arylsulphonates (e.g. methansulphonates or p-toluenesulphonates), phosphates, trifluoroacetates, acetates, citrates, succinates, tartrates, lactates, malates, fumarates and maleates.
  • the solvates may, for example, be hydrates.
  • references hereinafter to a compound according to the invention include both compounds of formula (I) and their pharmaceutically acceptable salts and their pharmaceutically acceptable solvates.
  • the invention provides a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof in an isolated form.
  • isolated form is meant a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof which is in an uncombined form.
  • an isolated form of the compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof does not include the compound of formula (I) produced in vivo by the metabolism of 4-(S)-(4-Acetyl-piperazin-1-yl)-2-(R)-(4- fluoro-2-methyl-phenyl)-piperidine-1-carboxylic acid, [1-(R)-(3,5-bis-trifluoromethyl- phenyl)-ethyl]-methylamide.
  • the invention provides a substantially pure compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof.
  • the compound of formula (I) as represented above includes a racemic mixture of these two diastereoisomers and each diastereoisomer individually. It is to be understood that all diastereoisomers and mixtures thereof are encompassed within the scope of the present invention.
  • the wedge shaped bond indicates that the bond is above the plane of the paper and is referred to as ⁇ configuration.
  • the broken bond indicates that the bond is below the plane of the paper and is in the ⁇ configuration.
  • the ⁇ configuration at the 2 position corresponds to the R configuration and the ⁇ at 4 position corresponds to the S configuration.
  • the assignment of the R or S configuration at the 2 and the 4 positions has been made according to the rules of Cahn, lngold and Prelog , Experientia 1956,12, 81.
  • the compound of formula (I) may exist in one or more crystalline forms and the crystalline forms of the compound of formula (I) may exist as polymorphs, which are included in the present invention.
  • the compound of the invention is a human metabolite of 4-(S)-(4-Acetyl-piperazin-1-yl)-2- (R)-(4-fluoro-2-methyl-phenyl)-piperidine-1 -carboxylic acid, [1 -(R)-(3,5-bis-trifluoromethyl- phenyl)-ethyl]-methylamide which is described in WO 02/32867.
  • the compound of the invention is itself an antagonist of tachykinin receptors, including substance P and other neurokinins, both in vitro and in vivo and is thus of use in the treatment of conditions mediated by tachykinins, including substance P and other neurokinins.
  • Tachykinins are a family of peptides that share a common carboxyl-terminal sequence (Phe-X-Gly-Leu-Met-NH2). They are actively involved in the physiology of both lower and advanced lifeforms. In mammalian lifeforms the main tachykinins are subtance P (SP), Neurokinin A (NKA) and Neurokinin B (NKB) which act as neurotransmitters and neuromodulators. Mammalian tachykinins may contribute to the pathophysiology of a number of human diseases.
  • NK1 SP-preferring
  • NK2 NKA-preferring
  • NK3 NKB-preferring
  • CNS central nervous
  • the compounds of the invention are antagonists of the NK1 receptor.
  • NK-] -receptor binding affinity has been determined in vitro in filtration binding assay by measuring the compounds' ability to displace [ 3 H]-Substance P (SP) from recombinant human NK-
  • ligand binding was performed in 0.4 ml of 50 mM HEPES, pH 7.4, containing 3 mM MnCI 2 , 0.02% BSA, 0.5 nM [ 3 H]-Substance P (30-56 Ci/mmol Amersham), a final membrane protein concentration of 30-50 ⁇ g/ml, and the test compounds.
  • the incubation proceeded at room temperature for 40 min and was stopped by filtration.
  • Non-specific binding was determined using excess of substance P (1 ⁇ M) and represents about 6-10% of the total binding.
  • IC 50 values of each compound were determined by an 8-point 10x- dilution inhibition curve.
  • pKj values were calculated using the K D of [ 3 H]-Substance P determined in a separate experiment.
  • Compounds of the invention are further characterised in a functional assay for the determination of their effect to inhibit the intracellular calcium increase induced by SP in Human-NK-
  • the action of the compounds of the invention at the NK- ) receptor may be determined by using conventional animal models.
  • receptor was determined using the gerbil foot tapping model as described by Rupniak & Williams, Eur. J. of Pharmacol., 1994.
  • Compounds of the invention are useful in the treatment of CNS disorders and psychotic disorders, in particular in the treatment or prevention of depressive states and /or in the treatment of anxiety as defined in Diagnostic Statistical of Mental Disorder (DSM) IV edition edit by American Psychiatric Association and International Classification Diseases 10th revision ( ICD 10).
  • DSM Diagnostic Statistical of Mental Disorder
  • ICD 10 International Classification Diseases 10th revision
  • depressive states include depressive mood episodes, depressive disorders, bipolar disorders, other mood, psychotic and adjustment disorders, premenstrual and dysphroic disorder(PMDD).
  • depressive mood episodes include major depressive episodes and mixed episodes.
  • Depressive disorders include Major Depressive Disorder (MDD), single or recurrent episodes (with or without psychotic features, catatonic features, melancholic features, atypical features, anxious depression, or postpartum onset), dysthymic disorder (with early or late onset and with or without atypical features) and depressive disorder not otherwise specified.
  • Bipolar disorders include bipolar I and Il disorders, cyclothymic disorder and bipolar disorder not otherwise specified.
  • mood, psychotic and adjustment disorders include neurotic depression; mood disorders due to general medical conditions including, but not limited to, myocardial infarction, diabetes, miscarriage, abortion, dementia of the Alzheimer's type (with early or late onset) with depressed mood, vascular dementia with depressed mood; substance-induced mood disorders including, but not limited to, depression induced by alcohol, amphetamines, cocaine, hallucinogens, inhalants, opioids, phencyclidines, sedatives, hypnotics, anxiolytics and other substances; schizoaffective disorder of the depressed type; adjustment disorder with depressed mood; adjustment disorder with mixed anxiety and depressed mood.
  • anxiety includes panic attacks, agoraphobia, anxiety disorders, adjustment disorders and separation anxiety disorder and premenstrual dysphroic disorder(PMDD).
  • anxiety disorders include panic disorder with or without agoraphobia, agoraphobia without a history of panic disorder, specific phobia, social phobia (social anxiety disorder), obsessive-compulsive disorder, acute and post-traumatic stress disorders, generalised anxiety disorders, anxiety disorder due to a general medical condition, substance-induced anxiety disorder, anxiety disorder not otherwise specified and mixed anxiety-depression disorders.
  • Adjustment disorders include adjustment disorder with anxiety and adjustment disorder with mixed anxiety and depressed mood.
  • Compounds of the invention are useful as analgesics.
  • traumatic pain such as postoperative pain
  • traumatic avulsion pain such as brachial plexus
  • chronic pain such as arthritic pain such as occurring in osteo-, rheumatoid or psoriatic arthritis
  • neuropathic pain such as post-herpetic neuralgia, trigeminal neuralgia, segmental or intercostal neuralgia, fibromyalgia, causalgia, peripheral neuropathy, diabetic neuropathy, chemotherapy-induced neuropathy, AIDS related neuropathy, occipital neuralgia, geniculate neuralgia, glossopharyngeal neuralgia, reflex sympathetic dystrophy, phantom limb pain
  • various forms of headache such as migraine, acute or chronic tension headache, temporomandibular pain, maxillary sinus pain, cluster headache
  • odontalgia cancer pain; pain of visceral origin; gastrointestinal pain; nerve entrapment pain; sport's injury pain; dysmennorrho
  • Compounds of the invention are also useful in the treatment of sleep disorders or sleep disturbances including dysomnia, primary insomnia, sleep apnea, narcolepsy, and circadian admiric disorders or in the treatment of sleep disorders and/or sleep disturbances related or due to other disorders.
  • Cognitive disorders include dementia, amnestic disorders and cognitive disorders not otherwise specified.
  • compounds of the invention are also useful as memory and/or cognition enhancers in healthy humans with no cognitive and/or memory deficit.
  • Compounds of the invention are also useful in the treatment of tolerance to and dependence on a number of substances. For example, they are useful in the treatment of dependence on nicotine, alcohol, caffeine, phencyclidine (phencyclidine like compounds) or in the treatment of tolerance to and dependence on opiates (e.g. cannabis, heroin, morphine) or benzodiazepines; in the treatment of addiction to cocaine, sedative ipnotic, amphetamine or amphetamine-related drugs (e.g. dextroamphetamine, methylamphetamine) or a combination thereof.
  • opiates e.g. cannabis, heroin, morphine
  • amphetamine or amphetamine-related drugs e.g. dextroamphetamine, methylamphetamine
  • Compounds of the invention are also useful as anti-inflammatory agents.
  • they are useful in the treatment of inflammation in asthma, influenza, chronic bronchitis and rheumatoid arthritis; in the treatment of inflammatory diseases of the gastrointestinal tract such as Crohn's disease, ulcerative colitis, inflammatory bowel disease and nonsteroidal anti-inflammatory drug induced damage; inflammatory diseases of the skin such as herpes and eczema; inflammatory diseases of the bladder such as cystitis and urge incontinence, overactive bladder and eye and dental inflammation.
  • Compounds of the invention are also useful in the treatment of allergic disorders, in particular allergic disorders of the skin such as urticaria, and allergic disorders of the airways such as rhinitis.
  • Compounds of the invention are also useful in the treatment or prevention of schizophrenic disorders including paranoid schizophrenia, disorganised schizophrenia, catatonic schizophrenia, undifferentiated schizophrenia, residual schizophrenia.
  • Emesis i.e. nausea, retching and vomiting.
  • Emesis includes acute emesis, delayed emesis and anticipatory emesis.
  • the compounds of the invention are useful in the treatment of emesis however induced.
  • emesis may be induced by drugs such as cancer chemotherapeutic agents such as alkylating agents, e.g. cyclophosphamide, carmustine, lomustine and chlorambucil; cytotoxic antibiotics, e.g. dactinomycin, doxorubicin, mitomycin-C and bleomycin; anti-metabolites, e.g.
  • cytarabine methotrexate and 5- fluorouracil
  • vinca alkaloids e.g. etoposide, vinblastine and vincristine
  • others such as cisplatin, dacarbazine, procarbazine and hydroxyurea; and combinations thereof
  • radiation sickness e.g. irradiation of the thorax or abdomen, such as in the treatment of cancer; poisons; toxins such as toxins caused by metabolic disorders or by infection, e.g.
  • gastritis or released during bacterial or viral gastrointestinal infection; pregnancy; vestibular disorders, such as motion sickness, vertigo, dizziness and Meniere's disease; post-operative sickness; gastrointestinal obstruction; reduced gastrointestinal motility; visceral pain, e.g. myocardial infarction or peritonitis; migraine; increased intercranial pressure; decreased intercranial pressure (e.g.
  • GSD gastro-oesophageal reflux disease
  • erosive GERD and symptomatic GERD or non erosive GERD acid indigestion, over-indulgence of food or drink, acid stomach, sour stomach, waterbrash/regurgitation
  • heartburn such as episodic heartburn, nocturnal heartburn, and meal-induced heartburn, dyspepsia and functional dyspepsia.
  • Compounds of the invention are also useful in the treatment of gastrointestinal disorders such as irritable bowel syndrome, gastro-oesophageal reflux disease (GERD) such as erosive GERD and symptomatic GERD or non erosive GERD, acid indigestion, overindulgence of food or drink, acid stomach, sour stomach, waterbrash/regurgitation, heartburn, such as episodic heartburn, nocturnal heartburn, and meal-induced heartburn, dyspepsia and functional dyspepsia (such as ulcer-like dyspepsia, dysmotility-like dyspepsia and unspecified dyspepsia), chronic constipation; skin disorders such as psoriasis, pruritis and sunburn; vasospastic diseases such as angina, vascular headache and Reynaud's disease; cerebral ischeamia such as cerebral vasospasm following subarachnoid haemorrhage; fibrosing and collagen diseases
  • the compounds of the invention are also useful in premenstrual dysphoric disorder (PMDD), in chronic fatigue syndrome and Multiple sclerosis.
  • the compound of the invention may be administered in combination with other active substances such as anti-nauseants (including 5HT3 antagonists and dexamethasone), serotonin agonists, selective serotonin reuptake inhibitors (SSRI), noradrenaline re-uptake inhibitors (SNRI), tricyclic antidepressants dopaminergic antidepressants or inhibitors of sodium channels.
  • active substances such as anti-nauseants (including 5HT3 antagonists and dexamethasone), serotonin agonists, selective serotonin reuptake inhibitors (SSRI), noradrenaline re-uptake inhibitors (SNRI), tricyclic antidepressants dopaminergic antidepressants or inhibitors of sodium channels.
  • Suitable 5HT3 antagonists which may be used in combination of the compounds of the invention include for example ondansetron, granisetron and metoclopramide.
  • Suitable serotonin agonists which may be used in combination with the compounds of the invention include sumatriptan, rauwolscine, yohimbine and metoclopramide.
  • Suitable SSRIs which may be used in combination with the compounds of the invention include fluoxetine, citalopram, femoxetine, fluvoxamine, paroxetine, indalpine, sertraline and zimeldine.
  • Suitable SNRIs which may be used in combination with the compounds of the invention include venlafaxine and reboxetine.
  • Suitable tricyclic antidepressants which may be used in combination with the compounds of the invention include imipramine, amitriptiline, chlomipramine and nortriptyline.
  • Suitable dopaminergic antidepressants which may be used in combination with the compounds of the invention include bupropion and amineptine.
  • Suitable inhibitors of voltage-gated sodium channels which may be used in combination with the compound of the invention include lamotrigine, carbamazepine, and phenytoin.
  • the two or more compounds of the combination or composition may be administered simultaneously (either in the same or different pharmaceutical formulations) or sequentially.
  • the invention therefore provides a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof for use in therapy, in particular in human medicine.
  • a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof in the preparation of a medicament for use in the treatment of conditions mediated by tachykinins (including substance P and other neurokinins).
  • a method for the treatment of a mammal including man, in particular in the treatment of conditions mediated by tachykinins, including substance P and other neurokinins and comprising administration of an effective amount of a compound of formula (I) or a pharmaceutically acceptable salts and solvates thereof.
  • a compound of formula (I) may be administered as the raw chemical but the active ingredient is preferably presented as a pharmaceutical formulation.
  • the invention also provides a pharmaceutical composition which comprises at least one compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof formulated for administration by any convenient route.
  • a pharmaceutical composition which comprises at least one compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof formulated for administration by any convenient route.
  • Such compositions are preferably in a form adapted for use in medicine, in particular human medicine, and can conveniently be formulated in a conventional manner using one or more pharmaceutically acceptable carriers or excipients.
  • a compound of formula (I) may be formulated for oral, buccal, parenteral, topical (including ophthalmic and nasal), depot or rectal administration or in a form suitable for administration by inhalation or insufflation (either through the mouth or nose).
  • the pharmaceutical compositions may take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g. lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g. magnesium stearate, talc or silica); disintegrants (e.g. potato starch or sodium starch glycollate); or wetting agents (e.g. sodium lauryl sulphate).
  • binding agents e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose
  • fillers e.g. lactose, microcrystalline cellulose or calcium hydrogen phosphate
  • lubricants e.g. magnesium stearate, talc or silica
  • disintegrants e.g. potato starch or sodium starch glycollate
  • Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use.
  • Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g. sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (e.g. lecithin or acacia); non-aqueous vehicles (e.g. almond oil, oily esters, ethyl alcohol or fractionated vegetable oils); and preservatives (e.g. methyl or propyl-p-hydroxybenzoates or sorbic acid).
  • the preparations may also contain buffer salts, flavouring, colouring and sweetening agents as appropriate.
  • Preparations for oral administration may be suitably formulated to give controlled release of the active compound.
  • composition may take the form of tablets or be formulated in a conventional manner.
  • the compound of the invention may be formulated for parenteral administration by bolus injection or continuous infusion.
  • Formulations for injection may be presented in unit dosage form, e.g. in ampoules or in multi-dose containers, with an added preservative.
  • the compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising and/or dispersing agents.
  • the active ingredient may be in powder form for constitution with a suitable vehicle, e.g. sterile pyrogen-free water, before use.
  • the compound of the invention may be formulated for topical administration in the form of ointments, creams, gels, lotions, pessaries, aerosols or drops (e.g. eye, ear or nose drops).
  • Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents.
  • Ointments for administration to the eye may be manufactured in a sterile manner using sterilised components.
  • Lotions may be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilising agents, dispersing agents, suspending agents, thickening agents, or colouring agents. Drops may be formulated with an aqueous or non- aqueous base also comprising one or more dispersing agents, stabilising agents, solubilising agents or suspending agents. They may also contain a preservative.
  • the compound of the invention may also be formulated in rectal compositions such as suppositories or retention enemas, e.g. containing conventional suppository bases such as cocoa butter or other glycerides.
  • the compound of the invention may also be formulated as depot preparations. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection.
  • the compound of the invention may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
  • the compounds of the invention may be formulated as solutions for administration via a suitable metered or unitary dose device or alternatively as a powder mix with a suitable carrier for administration using a suitable delivery device.
  • a proposed dose of the compounds of the invention is 1 to about IOOOmg per day. It will be appreciated that it may be necessary to make routine variations to the dosage, depending on the age and condition of the patient and the precise dosage will be ultimately at the discretion of the attendant physician or veterinarian.
  • the dosage will also depend on the route of administration and the particular compound selected. Thus, for parenteral administration a daily dose will typically be in the range of 1 to about 100 mg, preferably 1 to 80 mg per day. For oral administration a daily dose will typically be within the range 1 to 300 mg e.g. 1 to 100 mg.
  • the compound of formula (I), or pharmaceutically acceptable salts and solvates thereof, may be prepared by the general methods outlined hereinafter.
  • the compound of formula (I) may be prepared by cyclisation of a compound of formula (H) in the presence of an oxidative reagent using for example Osmium tetraoxide and sodium periodate.
  • the reaction is preferably carried out in a solvent or a mixture of solvents such as water and tetrahydrofuran.
  • the compound of formula (II), may be prepared by N-allylation of a compound of formula (III)
  • the reaction may be carried out in an aprotic solvent such as dichloromethane, tetrahydrofuran, N,N-dimethylformamide or acetonitrile and in the presence of a suitable base (e.g sodium hydrogencarbonate).
  • aprotic solvent such as dichloromethane, tetrahydrofuran, N,N-dimethylformamide or acetonitrile
  • a suitable base e.g sodium hydrogencarbonate
  • the compound of formula (III) may be prepared by reductive N-alkylation of a compound of formula (V), with N-acetylethylenediamine(VI) in a solvent such as an alcohol (i.e methanol) and in the presence of a suitable metal reducing agent such as sodium borohydride or sodium triacetoxyborohydride.
  • a solvent such as an alcohol (i.e methanol)
  • a suitable metal reducing agent such as sodium borohydride or sodium triacetoxyborohydride.
  • a compound of formula (I) as a salt for example a pharmaceutically acceptable salt
  • this may be achieved by reacting the compound of formula (I) in the form of the free base with an appropriate amount of suitable acid and in a suitable solvent such as an alcohol (e.g. ethanol or methanol), an ester (e.g. ethyl acetate) or an ether (e.g. diethyl ether or tetrahydrofuran).
  • a suitable solvent such as an alcohol (e.g. ethanol or methanol), an ester (e.g. ethyl acetate) or an ether (e.g. diethyl ether or tetrahydrofuran).
  • Pharmaceutically acceptable salts may also be prepared from other salts, including other pharmaceutically acceptable salts, of the compounds of formula (I) using conventional methods.
  • the compound of formula (V) is a known compound and its preparation is described in
  • Mass spectra were taken on a 4 Il triple quadrupole Mass Spectrometer (Micromass UK) or on a Agilent MSD 1100 Mass Spectrometer, operating in ES (+) and ES (-) ionization mode or on a Agilent LC/MSD 1100 Mass Spectrometer, operating in ES (+) and ES (-) ionization mode coupled with HPLC instrument Agilent 1100 Series [LC/MS - ES (+):analysis performed on a Supelcosil ABZ +Plus (33x4.6 mm, 3 ⁇ m) (mobile phase: 100% [water +0.1% HCO 2 H] for 1 min, then from 100% [water +0.1% HCO 2 H] to 5% [water +0.1 % HCO 2 H] and 95% [CH 3 CN ] in 5 min,
  • HPLC walk -up refers to HPLC analysis performed on a Luna C18 (mobile phase: from
  • T.I. c. refers to thin layer chromatography on 0.25 mm silica gel plates (60F-254 Merck) and visualized with UV light.
  • phase separations performed by using microfiltration devices phase separation cartridge with polypropylene frit by Whatman or Alltech.
  • SCX means: SCX-cartridges (loading 0.75mmol ⁇ g) by Varian.
  • Diastereoisomer 1 or Diastereoisomer 2 refer to a single diastereoisomer of formula (I) wherein the absolute stereochemistry of the carbon atom shown as * in formula (I) is unknown
  • Example 1a (Diastereoisomer 1 ) and Example 1b(Diastereoisomer 2)
  • UV wavelenght range 220 nm Analysis time 40 min
  • Example 1a Diastereoisomer 1 190 mg (retention time 23.3 min) and Example 1b(Diastereoisomer 2) 180 mg ( retention time 31.4 min) were obtained.
  • the active ingredient is blended with the other excipients.
  • the blend can be compressed to form tablets using appropriate punches.
  • the tablets can be coated using conventional techniques and coatings.
  • the active ingredient is blended with microcrystalline cellulose and then filled into suitable capsules.
  • Buffer solution pH 3.5 (3.0 - 4.0) suitable for injection qs to 10 ml. (e.g. citrate buffer in sterile water for injection or NaCI 0.9%).
  • the formulation may be packaged in glass or plastic vials or ampules.
  • the formulation may be administered by bolus injection or infusion, e.g. after dilution with D5W or 0.9% NaCI.
  • NK-I receptor binding affinity method measuring in vitro the compounds' ability to displace [3H] - substance P (SP) from recombinant human NK ⁇
  • Example 1a pK1 10.6
  • Example 1b pK1 10.5
  • the ability of the compounds of the invention to penetrate the central nervous system and to bind at the NK1 receptor may be determined using the gerbill foot tapping model as described by Rupniak & Williams, Eur. Jour, of Pharmacol., 1994.
  • the compound was oral administered and one hour later an NK1 agonist (e.g. delta- Aminovaleryl 6 [Pro 9 ,Me-Leu 10 ]-substance P (7-11 ) (3pmol in 5 ⁇ l_ icv) was infused directly in the cerebral ventricules of the animals.
  • the duration of hind foot tapping induced by the NK1 agonist e.g.
  • delta-Aminovaleryl 6 [Pro 9 ,Me-Leu 10 ]-substance P (7-11 )) was recorded continuosly for 3 min using a stopclock.
  • the compounds may be administered subcutaneously or intraperitoneally. Results obtained for compounds of the invention when given by oral administration are given in the following table

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un composé représenté par la formule (I) ou un sel ou un solvate pharmaceutiquement acceptables de ce composé, un procédé permettant de préparer ces composés, l'utilisation de ces composés pour le traitement de maladies dont les tachykinines sont des médiateurs, et des compositions pharmaceutiques contenant ces composés.
PCT/EP2006/007080 2005-07-18 2006-07-14 Composes chimiques Ceased WO2007009758A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0514705.3A GB0514705D0 (en) 2005-07-18 2005-07-18 Chemical compounds
GB0514705.3 2005-07-18

Publications (2)

Publication Number Publication Date
WO2007009758A2 true WO2007009758A2 (fr) 2007-01-25
WO2007009758A3 WO2007009758A3 (fr) 2007-04-19

Family

ID=34897390

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/007080 Ceased WO2007009758A2 (fr) 2005-07-18 2006-07-14 Composes chimiques

Country Status (2)

Country Link
GB (1) GB0514705D0 (fr)
WO (1) WO2007009758A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010007032A1 (fr) * 2008-07-14 2010-01-21 Glaxo Wellcome Manufacturing Pte Ltd Urées à base de pipéridine en tant qu’antagonistes du nk1

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0025354D0 (en) * 2000-10-17 2000-11-29 Glaxo Group Ltd Chemical compounds
GB0203022D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
TWI283241B (en) * 2002-05-29 2007-07-01 Tanabe Seiyaku Co Novel piperidine compound
EP1638935A1 (fr) * 2003-06-19 2006-03-29 Pfizer Products Inc. Antagoniste de nk1

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010007032A1 (fr) * 2008-07-14 2010-01-21 Glaxo Wellcome Manufacturing Pte Ltd Urées à base de pipéridine en tant qu’antagonistes du nk1

Also Published As

Publication number Publication date
GB0514705D0 (en) 2005-08-24
WO2007009758A3 (fr) 2007-04-19

Similar Documents

Publication Publication Date Title
US7060702B2 (en) Chemical compounds
US20100152446A1 (en) Piperidine Derivatives
US20040209893A1 (en) Chemical compounds
AU2001295723A1 (en) Chemical compounds
US7214680B2 (en) 2-substituted 1-arylpiperazines as tachykinin antagonists and/or serotonin reuptake inhibitors
WO2007009758A2 (fr) Composes chimiques
US20080249132A1 (en) Piperidine Carboxyamide Derivate Suitable as Tachykinin Receptor Antagonist
WO2007009777A1 (fr) Composes chimiques
US20040157858A1 (en) Piperazine derivatives as tachykinin antagonists
HK1072251B (en) Piperidine derivatives
HK1089752A (en) Composition comprising a tachykinin receptor antagonist and a selective serotonin reuptake inhibitor

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06762682

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 06762682

Country of ref document: EP

Kind code of ref document: A2